

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 November 2020 (05.11.2020)



(10) International Publication Number
WO 2020/223702 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) G01N 33/574 (2006.01)
A61P 37/06 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2020/031181

(22) International Filing Date:

01 May 2020 (01.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/841,732 01 May 2019 (01.05.2019) US

(71) Applicants: **NEW YORK UNIVERSITY** [US/US]; 70 Washington Square South, New York, NY 10012 (US).
PURETECH HEALTH, LLC [US/US]; 501 Boylston Street, Suite 6102, Boston, MA 02116 (US).

(72) Inventors: **KOIDE, Shohei**; 70 Washington Square South, New York, NY 10012 (US). **MILLER, George**; 70 Washington Square South, New York, NY 10012 (US). **KOIDE, Akiko**; 70 Washington Square South, New York, NY 10012 (US). **CHEN, Linxiao**; 70 Washington Square South, New York, NY 10012 (US). **FILIPOVIC, Aleksandra**; 87 Ful-

ham Palace Road, London W6 8JA (GB). **ELENKO, Eric**; 1 Franklin Street, Apt. 1903, Boston, MA 02110 (US). **BOLEN, Joseph**; 135 Clarendon Street, Apartment 11V, Boston, MA 02116 (US).

(74) Agent: **WATT, Rachel, S.** et al.; Hodgson Russ LLP, The Guaranty Building, 140 Pearl Street, Suite 100, Buffalo, NY 14202-4040 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

(57) Abstract: Disclosed herein are methods for treating solid tumors (e.g., pancreatic adenocarcinoma (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC)), or Cholangiocarcinoma and others), including, but not limited to, metastatic tumors, using an anti-Galectin-9 antibody.




Fig. 7A

WO 2020/223702 A1

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*